Table 1.
Demographic data for the enrolled patients.
| Covariates | |
|---|---|
| Age (years, median, interquartile range) | 69.0 (58.5–75.5) |
| Sex (number, %) | |
| Male | 31 (72.1) |
| Female | 12 (27.9) |
| Body mass index (kg/m2, median, interquartile range) | 23.3 (20.6–25.5) |
| The Eastern Cooperative Oncology Group performance status (number, %) |
|
| 0 | 21 (48.8) |
| 1 | 15 (34.9) |
| 2 | 4 (9.3) |
| 3 | 3 (7.0) |
| IMDC risk classification (number, %) | |
| Intermediate | 25 (58.1) |
| Poor | 18 (41.9) |
| Histology | |
| Clear cell renal cell carcinoma | 27 (62.8) |
| Papillary renal cell carcinoma | 1 (2.3) |
| Unknown | 15 (34.9) |
| Neutrophil counts (*109/L, median, interquartile range) | 1.4 (1.1–1.8) |
| Lymphocyte counts (*109/L, median, interquartile range) | 4.5 (3.8–5.6) |
| Platelet counts (*109/L, median, interquartile range) | 265 (213–348) |
| Systemic immune inflammation index (median, interquartile range) |
1045.2 (590.2–1862.2) |
| Neutrophil-to-lymphocyte ratio (median, interquartile range) | 4.1 (2.7–5.9) |
| Platelet-to-lymphocyte ratio (median, interquartile range) | 215.6 (144.7–316.3) |
| The patients who underwent surgery before administration of NIVO + IPI (number, %) |
20 (46.5) |
| Number of metastatic sites | |
| 0 | 4 (9.3) |
| 1 | 12 (27.9) |
| 2 | 14 (32.6) |
| ≥3 | 13 (30.2) |
| Total number of metastatic sites (number, %) | |
| Lung | 20 (46.5) |
| Lymph node | 14 (32.6) |
| Bone | 14 (32.6) |
| Liver | 11 (25.6) |
| Brain | 6 (14.0) |
| Adrenal gland | 5 (11.6) |
| Pancreas | 2 (4.7) |
| Local recurrence | 2 (4.7) |
| Others | 4 (9.3) |
IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; NIVO + IPI, combination nivolumab plus ipilimumab.